title: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
abstract: BACKGROUND
  Women with BRCA1 or BRCA2 mutation are often advised to undergo preventive oophorectomy. The effectiveness of this intervention has not been prospectively evaluated in a large cohort.
  
  
  OBJECTIVE
  To estimate the incidence of ovarian, fallopian tube, and primary peritoneal cancer in women who carry a deleterious mutation in BRCA1 or BRCA2. To estimate the reduction in risk of these cancers associated with a bilateral prophylactic salpingo-oophorectomy.
  
  
  METHODS
  Women known to carry a BRCA1 or BRCA2 mutation were identified from an international registry between 1992 and 2003. A total of 1828 carriers at 1 of 32 centers in Canada, the United States, Europe, and Israel completed questionnaires at baseline and follow-up. Participants were observed from the date of study entry until: diagnosis of ovarian, fallopian tube, or peritoneal cancer; death; or the date of the most recent follow-up.
  
  
  METHODS
  Participants were divided into women who had undergone bilateral prophylactic oophorectomy and those who had not.
  
  
  METHODS
  The incidence of ovarian, peritoneal, and fallopian tube cancer was determined by survival analysis. The risk reduction associated with prophylactic salpingo-oophorectomy was evaluated by a time-dependent survival analysis, adjusting for covariates.
  
  
  RESULTS
  After a mean follow-up of 3.5 years, 50 incident ovarian, fallopian tube, and peritoneal cancer cases were reported in the cohort. Of the 1828 women, 555 (30%) underwent a bilateral prophylactic salpingo-oophorectomy prior to study entry, 490 (27%) underwent the procedure after entering the study, and 783 (43%) did not undergo the procedure. There were 32 incident cancers diagnosed in women with intact ovaries (1015/100,000 per year). Eleven cancer cases were identified at the time of prophylactic oophorectomy and 7 were diagnosed following prophylactic oophorectomy (217/100,000 per year). The estimated cumulative incidence of peritoneal cancer is 4.3% at 20 years after oophorectomy. The overall (adjusted) reduction in cancer risk associated with bilateral oophorectomy is 80% (multivariate hazard ratio = 0.20; 95% confidence interval, 0.07-0.58; P = .003).
  
  
  CONCLUSIONS
  Oophorectomy is associated with reduced risk of ovarian and fallopian tube cancer in high-risk women, although there is a substantial residual risk for peritoneal cancer in BRCA1 and BRCA2 mutation carriers following prophylactic salpingo-oophorectomy.
authors.affiliation: Centre for Research in Women's Health, Toronto-Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada.
authors.forename: Amy
authors.initials: A
authors.lastname: Finch
authors.forename: Mario
authors.initials: M
authors.lastname: Beiner
authors.forename: Jan
authors.initials: J
authors.lastname: Lubinski
authors.forename: Henry T
authors.initials: HT
authors.lastname: Lynch
authors.forename: Pal
authors.initials: P
authors.lastname: Moller
authors.forename: Barry
authors.initials: B
authors.lastname: Rosen
authors.forename: Joan
authors.initials: J
authors.lastname: Murphy
authors.forename: Parviz
authors.initials: P
authors.lastname: Ghadirian
authors.forename: Eitan
authors.initials: E
authors.lastname: Friedman
authors.forename: William D
authors.initials: WD
authors.lastname: Foulkes
authors.forename: Charmaine
authors.initials: C
authors.lastname: Kim-Sing
authors.forename: Teresa
authors.initials: T
authors.lastname: Wagner
authors.forename: Nadine
authors.initials: N
authors.lastname: Tung
authors.forename: Fergus
authors.initials: F
authors.lastname: Couch
authors.forename: Dominique
authors.initials: D
authors.lastname: Stoppa-Lyonnet
authors.forename: Peter
authors.initials: P
authors.lastname: Ainsworth
authors.forename: Mary
authors.initials: M
authors.lastname: Daly
authors.forename: Babara
authors.initials: B
authors.lastname: Pasini
authors.forename: Ruth
authors.initials: R
authors.lastname: Gershoni-Baruch
authors.forename: Charis
authors.initials: C
authors.lastname: Eng
authors.forename: Olufunmilayo I
authors.initials: OI
authors.lastname: Olopade
authors.forename: Jane
authors.initials: J
authors.lastname: McLennan
authors.forename: Beth
authors.initials: B
authors.lastname: Karlan
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Weitzel
authors.forename: Ping
authors.initials: P
authors.lastname: Sun
authors.forename: Steven A
authors.initials: SA
authors.lastname: Narod
mesh_terms: D000328:Adult; D000368:Aged; D015331:Cohort Studies; D005185:Fallopian Tube Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control*; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control*; D010052:Ovariectomy; D010534:Peritoneal Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control*; D012306:Risk; D016019:Survival Analysis